Conclusion
We are hypothesizing that the profuse presence of ACE 2 and its upregulation in different pathological conditions making patients more susceptible to SARS-CoV-2 infection and can contribute to an increase in co-morbidity and mortality. COVID-19 is a global concern and its pathophysiology is very complex which creating an illusion towards the use of first-line drugs in the treatments of preeclampsia, cardiovascular diseases, diabetes and its complications, asthma, NASH, immune-related diseases and cancer. Hence, there is an urgent need for care to those patients who have SARS-CoV-2 infection underlying with multiple diseases and its delay in diagnosis may increase the severity and mortality in comorbid conditions due to multi-organ transmission of infection with a heavy load of virus and cytokine storm (Figure 1). Hence targeting the interaction of SARS-CoV-2 to ACE 2 could be the future novel therapeutic approach to alleviate the multi-organ transmission and failure.